KRAS polymorphisms are associated with survival of CRC in Chinese population

XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population

(2015) Qiong Dai et al.   MUTAGENESIS

A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer

(2013) Zhao-Hui Li et al.   TUMOR BIOLOGY

A let-7 KRAS rs712 polymorphism increases colorectal cancer risk

(2013) Xin-Min Pan et al.   TUMOR BIOLOGY

Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

(2012) Janne B Kjersem et al.   BMC CANCER

KRAS-LCS6 Genotype as a Prognostic Marker in Early-Stage CRC-Letter

(2012) B. M. Ryan et al.   CLINICAL CANCER RESEARCH

MicroRNA: future perspectives in colorectal cancer

(2012) Donato F. Altomare et al.   Colorectal Disease

Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Colorectal Cancer

(2012) E. Theodoratou et al.   JNCI-Journal of the National Cancer Institute

A Let-7 MicroRNA SNP in the KRAS 3'UTR Is Prognostic in Early-Stage Colorectal Cancer

(2011) K. M. Smits et al.   CLINICAL CANCER RESEARCH

The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

(2011) P. D. P. Pharoah et al.   CLINICAL CANCER RESEARCH

Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma

(2011) Wen-Yi Wang et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis

(2011) Trupti Paranjape et al.   LANCET ONCOLOGY

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

(2011) E S Ratner et al.   ONCOGENE

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

(2010) W. Zhang et al.   ANNALS OF ONCOLOGY

Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families

(2010) Antoinette Hollestelle et al.   BREAST CANCER RESEARCH AND TREATMENT

A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk

(2010) E. Ratner et al.   CANCER RESEARCH

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics

(2010) Prasun J. Mishra et al.   CELL CYCLE

Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan

(2010) F Graziano et al.   PHARMACOGENOMICS JOURNAL

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers

(2009) B. C. Christensen et al.   CARCINOGENESIS

A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk

(2008) L. J. Chin et al.   CANCER RESEARCH